

Long-Term Effectiveness of Cannabidiol Against Focal Seizures in Tuberous Sclerosis Complex: **Results From the GWPCARE6 Open-Label Extension Trial**

Joyce Y. Wu,¹ E. Martina Bebin,² Teresa Greco,³ Kelly C. Simontacchi⁴

¹Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL; ²University of Alabama School of Medicine, Chicago, IL; ³Jazz Pharmaceuticals, Inc, Chicago, IL; ³Jazz Pharmaceutica

Background

- Add-on cannabidiol (CBD) led to a significant reduction in seizures associated with tuberous sclerosis complex (TSC) in a randomized controlled trial (RCT; GWPCARE6), and most adverse events (AEs) were mild to moderate in severity.¹
- In an open-label extension (OLE) of GWPCARE6, seizure frequency remained lower than the RCT baseline throughout 156 weeks of CBD treatment.²
- The specific effect of long-term treatment with CBD on focal seizures in patients with TSC is not well characterized.

Objective

• To present the effectiveness and safety results of CBD treatment in patients with focal-onset seizures in the GWPCARE6 OLE.

Methods

- Patients who had completed treatment in the 16-week randomized controlled phase of GWPCARE6 were enrolled in the OLE.
- Eligible patients were aged 1–65 years, had a clinical TSC diagnosis, were experiencing ≥ 8 TSC-associated seizures during the 4-week RCT baseline period, and were taking ≥ 1 antiseizure medication at baseline.
- TSC-associated seizures included all countable focal motor seizures without impairment of awareness (FAS), focal seizures with impairment of awareness (FIAS), focal seizures evolving to bilateral motor seizures (FBTCS), and generalized seizures (tonic-clonic, tonic, clonic, or atonic).
- Patients entering the OLE started a 2-week blinded transition period, during which the blinded medication (CBD 25 mg/kg/d, CBD 50 mg/kg/d, or placebo) from the RCT was tapered down to 0, while CBD was simultaneously titrated up to 25 mg/kg/d; the dose could then be decreased or increased up to maximum 50 mg/kg/d based on response and tolerability.
- In this post hoc analysis, the effectiveness of CBD was evaluated as the percentage change from baseline in the 28-day monthly average and responder rates (\geq 50%, \geq 75%, and 100% reduction) of focal seizure frequency across 12-week intervals through 144 weeks of treatment.
- Safety endpoints included AEs, serious AEs, AEs leading to discontinuation, and deaths; safety results are reported for the full OLE treatment period.
- This trial was conducted with Epidiolex[®], and results do not apply to other CBD-containing products.

Results

Patient disposition, baseline characteristics, and CBD exposure

Table 1. Baseline characteristics and CBD exposure

Mean age, y

Sex, n (%)

Female

No. of ASMs

Most comm

Valproate

Vigabatrin

Levetiraceta

Clobazam

Lamotrigine

Baseline me

All focal sei

CBD exposur

Median time

Mean moda

Patients received trea CBD, cannabidiol; OLE

Conclusions


References: 1. Thiele EA et al. JAMA Neurol. 2021;78(3):285-292. 2. Thiele EA et al. Presented at the American Epilepsy Society (AES) Annual Meeting; Nashville, TN, USA; December 2–6, 2022. Acknowledgments: Writing and editorial assistance was provided by Sachi Yim, PhD, Ritu Pathak, PhD, and Dena McWain of Ashfield MedComms, an Inizio company, and funded by Jazz Pharmaceuticals, Inc. Support: The study was sponsored by Jazz Pharmaceuticals, Inc. **Disclosures:** All authors met the ICMJE authorship criteria and had full access to relevant data. Neither honoraria nor payments were made for authorship. **JYW** and **EMB** have consulted for, conducted studies funded by, or received honoraria for services provided to Jazz Pharmaceuticals, Inc. Epidiolex[®] is approved in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients ≥1 years of age.


Clinical Trial ID: NCT02544763

• Of 224 randomized patients in GWPCARE6, 199 (89%) entered the OLE; of these, 168 (84%) reported focal seizures, and 89 (45%) reported generalized seizures.

	Patients with focal seizures (N=168)	Median % reduction
years (min, max)	12.8 (1, 56)	
	69 (41)	
ls at baseline, median (min, max)	4 (0, 15)	
non (>20%) ASMs at baseline, n (%)		•
	68 (40)	Fi
	58 (35)	
tam	45 (27)	
	42 (25)	
le	37 (22)	Patients (%)
edian (Q1, Q3) monthly seizure frequency		
eizures	59 (29, 118)	
ure		
ne on CBD, days (range)	596 (18–1462)	
dal dose, mg/kg/d (SD)	27 (9)	•
eatment in the OLE for a maximum of 1 year, except in the US and Poland, where patients could co LE, open-label extension; Q1, first quartile; Q3, third quartile; SD, standard deviation.	ntinue beyond 1 year. ASM, antiseizure medication;	•

• In this post hoc, open-label analysis of patients with TSC in the GWPCARE6 OLE, CBD treatment was associated with a reduction in all focal seizure types through 144 weeks. • At least 50% reduction was reported by the majority of patients across focal seizure types through 144 weeks. • The safety profile was consistent with that observed in the overall CBD clinical development program. • Reductions in focal seizures are consistent with the overall findings of the study.





re 2. Treatment responder rates for focal seizures

Safety results

Table 2. Summary of AEs

Patients, n (%)	Patients with focal seizures (N=168)
TEAEs	
Any AEs	161 (96)
AEs leading to permanent discontinuation	9 (5)
Serious AEs	33 (20)
Deaths	1 (<1)
FEAEs reported in ≥10% of patients by MedDRA preferre	ed term
Diarrhea	79 (47)
Seizure	51 (30)
Decreased appetite	41 (24)
Pyrexia	38 (23)
Vomiting	36 (21)
Somnolence	31 (18)
Nasopharyngitis	28 (17)
Cough	25 (15)
Upper respiratory tract infection	24 (14)
Fall	18 (11)
Constipation	17 (10)
Influenza	17 (10)

• The most frequently reported serious AEs in \geq 5% of patients were seizure (9%) and status epilepticus (5%).

• The most frequently reported AEs leading to treatment discontinuation in $\geq 1\%$ of patients were seizure (2%), diarrhea (2%), liver function test increased (1%), and decreased appetite (1%).

• The one death during the study (due to cardiopulmonary failure) was deemed unrelated to treatment by the investigator

• Liver-related AEs in >1% of patients were increased alanine aminotransferase (n=12 [7%]) and increased aspartate aminotransferase (n=9[5%]).



Scan this code to access nis poster online. This code not for promotional purpose